




PHARMACEUTICAL 2017

Kura Oncology Inc.
Rank 79 of 292





PHARMACEUTICAL 2017

Kura Oncology Inc.
Rank 79 of 292

The relative strengths and weaknesses of Kura Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 124% points. The greatest weakness of Kura Oncology Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 170%, being 167% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	68,810
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,451
Liabilities, Non-Current	7,494
Other Assets	971
Other Compr. Net Income	69
Other Expenses	28,367
Other Liabilities	0
Other Net Income	807
Other Revenues	0
Property and Equipment	40
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	69,821
Liabilities	12,945
Expenses	28,367
Revenues	0
Stockholders Equity	56,876
Net Income	-27,560
Comprehensive Net Income	-27,526
Economic Capital Ratio	170%